Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab

BACKGROUND: Standard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma followed by nivolumab single-agent maintenance therapy. While many patients receive less than 4 doses due to immune-related toxicities, it is unclear if fewer doses of I/N may still...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Vincent T., Chamila Perera, Alahendra A., Sun, Yilun, Sitto, Merna, Waninger, Jessica J., Warrier, Govind, Green, Michael D., Fecher, Leslie A., Lao, Christopher D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296775/
https://www.ncbi.nlm.nih.gov/pubmed/35874737
http://dx.doi.org/10.3389/fimmu.2022.860421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296775/
https://www.ncbi.nlm.nih.gov/pubmed/35874737
http://dx.doi.org/10.3389/fimmu.2022.860421

Ejemplares similares